Olsen Maria Belland, Gregersen Ida, Sandanger Øystein, Yang Kuan, Sokolova Marina, Halvorsen Bente E, Gullestad Lars, Broch Kaspar, Aukrust Pål, Louwe Mieke C
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Section of Dermatology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
JACC Basic Transl Sci. 2021 Nov 3;7(1):84-98. doi: 10.1016/j.jacbts.2021.08.006. eCollection 2022 Jan.
The pathogenesis of cardiovascular disease (CVD) is complex and multifactorial, and inflammation plays a central role. Inflammasomes are multimeric protein complexes that are activated in a 2-step manner in response to infection or tissue damage. Upon activation the proinflammatory cytokines, interleukins-1β and -18 are released. In the last decade, the evidence that inflammasome activation plays an important role in CVD development became stronger. We discuss the role of different inflammasomes in the pathogenesis of CVD, focusing on atherosclerosis and heart failure. This review also provides an overview of existing experimental studies and clinical trials on inflammasome inhibition as a therapeutic target in these disorders.
心血管疾病(CVD)的发病机制复杂且具有多因素性,炎症在其中起着核心作用。炎性小体是多聚体蛋白复合物,在响应感染或组织损伤时以两步方式被激活。激活后会释放促炎细胞因子白细胞介素-1β和-18。在过去十年中,炎性小体激活在CVD发展中起重要作用的证据变得更加确凿。我们讨论不同炎性小体在CVD发病机制中的作用,重点关注动脉粥样硬化和心力衰竭。本综述还概述了关于炎性小体抑制作为这些疾病治疗靶点的现有实验研究和临床试验。